Vistagen Therapeutics (VTGN) Other Non-Current Liabilities (2011 - 2021)
Vistagen Therapeutics (VTGN) posted Other Non-Current Liabilities of $7.0 million for Q3 2021, up 5.66% sequentially from $6.6 million in Q2 2021, and up 23.09% YoY from $5.7 million in Q3 2020.
Vistagen Therapeutics (VTGN) Other Non-Current Liabilities (2011 - 2021) Analysis & Trends
Vistagen Therapeutics has reported Other Non-Current Liabilities for 9 years, with the latest figure at $7.0 million in Q3 2021.
- Quarterly Other Non-Current Liabilities rose 23.09% year-over-year to $7.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $7.0 million (up 23.09% YoY) and the FY2021 annual result came in at $6.3 million, up 25.16% from the prior year.
- Other Non-Current Liabilities improved to $7.0 million in Q3 2021 per VTGN's latest filing, from $6.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $7.0 million in Q3 2021 and troughed at $1.6 million in Q1 2017.
- A 5-year average of $4.1 million and a median of $4.1 million in 2019 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 75.05% in 2017, down 24.49% in 2017.
- Over 5 years, Other Non-Current Liabilities stood at $2.3 million in 2017, then soared by 47.43% to $3.5 million in 2018, then jumped by 35.59% to $4.7 million in 2019, then grew by 26.4% to $5.9 million in 2020, then gained by 18.33% to $7.0 million in 2021.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $7.0 million, $6.6 million, and $6.3 million for Q3 2021, Q2 2021, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 7.01 Mn |
| Jun 30, 2021 | 6.63 Mn |
| Mar 31, 2021 | 6.27 Mn |
| Dec 31, 2020 | 5.92 Mn |
| Sep 30, 2020 | 5.69 Mn |
| Jun 30, 2020 | 5.35 Mn |
| Mar 31, 2020 | 5.01 Mn |
| Dec 31, 2019 | 4.69 Mn |
| Sep 30, 2019 | 4.36 Mn |
| Jun 30, 2019 | 4.05 Mn |
| Mar 31, 2019 | 3.75 Mn |
| Dec 31, 2018 | 3.46 Mn |
| Sep 30, 2018 | 3.17 Mn |
| Jun 30, 2018 | 2.88 Mn |
| Mar 31, 2018 | 2.61 Mn |
| Dec 31, 2017 | 2.34 Mn |
| Sep 30, 2017 | 2.08 Mn |
| Jun 30, 2017 | 1.83 Mn |
| Mar 31, 2017 | 1.58 Mn |
| Dec 31, 2016 | 1.34 Mn |